Rayonier Advanced Materials

NYSE:RYAM Stock Report

Mkt Cap: US$495.8m

We’ve recently updated our valuation analysis.

Rayonier Advanced Materials Valuation

Is RYAM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RYAM?

Other financial metrics that can be useful for relative valuation.

RYAM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA9.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does RYAM's PS Ratio compare to its peers?

The above table shows the PS ratio for RYAM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.9x
ASPN Aspen Aerogels
3.6x40.4%US$542.5m
VHI Valhi
0.3xn/aUS$701.3m
CCF Chase
2.8xn/aUS$904.1m
FF FutureFuel
1xn/aUS$368.9m
RYAM Rayonier Advanced Materials
0.3x-0.6%US$495.8m

Price-To-Sales vs Peers: RYAM is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.9x).


Price to Earnings Ratio vs Industry

How does RYAM's PE Ratio compare vs other companies in the US Chemicals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.1%
n/an/an/a

Price-To-Sales vs Industry: RYAM is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Chemicals industry average (1.2x)


Price to Sales Ratio vs Fair Ratio

What is RYAM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RYAM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: RYAM is expensive based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).


Share Price vs Fair Value

What is the Fair Price of RYAM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RYAM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RYAM's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RYAM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.75
US$5.75
-25.8%
56.5%US$9.00US$2.50n/a2
Nov ’23US$4.47
US$3.95
-11.6%
51.9%US$6.00US$1.90n/a2
Oct ’23US$3.15
US$4.20
+33.3%
33.2%US$6.00US$2.60n/a3
Sep ’23US$4.24
US$4.20
-0.9%
33.2%US$6.00US$2.60n/a3
Aug ’23US$3.62
US$3.83
+5.9%
26.8%US$5.00US$2.50n/a3
Jul ’23US$2.79
US$4.67
+67.3%
20.2%US$6.00US$4.00n/a3
Jun ’23US$3.61
US$4.67
+29.3%
20.2%US$6.00US$4.00n/a3
May ’23US$5.13
US$6.80
+32.6%
8.7%US$7.40US$6.00n/a3
Apr ’23US$6.62
US$7.47
+12.8%
5.5%US$8.00US$7.00n/a3
Mar ’23US$5.76
US$7.50
+30.2%
9.4%US$8.00US$6.50n/a3
Feb ’23US$6.19
US$8.17
+31.9%
17.6%US$10.00US$6.50n/a3
Jan ’23US$5.71
US$8.17
+43.0%
17.6%US$10.00US$6.50n/a3
Dec ’22US$5.41
US$9.17
+69.4%
9.3%US$10.00US$8.00n/a3
Nov ’22US$7.49
US$9.17
+22.4%
9.3%US$10.00US$8.00US$4.473
Oct ’22US$7.74
US$8.83
+14.1%
9.6%US$10.00US$8.00US$3.153
Sep ’22US$7.08
US$8.83
+24.8%
9.6%US$10.00US$8.00US$4.243
Aug ’22US$6.97
US$8.83
+26.7%
7.1%US$9.50US$8.00US$3.623
Jul ’22US$6.64
US$9.50
+43.1%
15.5%US$11.50US$8.00US$2.793
Jun ’22US$7.95
US$10.17
+27.9%
15.2%US$11.50US$8.00US$3.613
May ’22US$9.09
US$11.50
+26.5%
3.6%US$12.00US$11.00US$5.133
Apr ’22US$9.46
US$11.50
+21.6%
3.6%US$12.00US$11.00US$6.623
Mar ’22US$10.70
US$7.67
-28.3%
52.5%US$11.00US$2.00US$5.763
Feb ’22US$7.43
US$6.67
-10.3%
51.0%US$10.00US$2.00US$6.193
Jan ’22US$6.52
US$5.07
-22.3%
46.3%US$7.70US$2.00US$5.713
Dec ’21US$7.26
US$6.00
-17.4%
47.5%US$10.00US$2.00US$5.414
Nov ’21US$3.43
US$5.63
+64.0%
50.8%US$10.00US$2.00US$7.494

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies